1. In Vivo

Funding The Future: Accelerating The Long Walk To Innovation

Good ideas must be paired with good people

 
• By Jo Shorthouse

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.  

accelerator people
Its the people involved in the deal that create company acceleration • Source: Shutterstock

Investment in ideas and new science takes research, and often faith to make innovation work. What may be a good idea on paper may not be scalable, or even answer an unmet need for patients. Entering the innovation arena before seed funding and venture capital are companies such as Deep Science Ventures and Oxford Science Enterprises, each taking its own approach to accelerating innovation.

Deep Science Ventures was borne from the philosophy of co-founders Mark Hammond and Dominic Falcão, both previously from Imperial College...

More from New Science

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy